Clinical Trial Approval for TSLP Bispecific Antibody Boosts SKB BIO-B and HBM HOLDINGS-B Shares

Stock News

03/10

Shares of SKB BIO-B (06990) and HBM HOLDINGS-B (02142) rose in morning trading. At the time of writing, SKB BIO-B was up 8.95%, trading at HK$414, while HBM HOLDINGS-B advanced 4.26% to HK$12. The gains followed news that on March 9, the CDE website indicated that the SKB575 (HBM7575) injection, jointly submitted by SKB BIO-B and HBM HOLDINGS-B, had received clinical trial approval for the treatment of atopic dermatitis. This marks the first bispecific antibody from the partners’ autoimmune disease collaboration pipeline to enter the clinical stage. It is reported that HBM7575/SKB575 targets thymic stromal lymphopoietin (TSLP) and an undisclosed target, featuring a dual mechanism of action. On one hand, it inhibits TSLP-mediated signaling pathways and the activation of Th2 immune cells by blocking the interaction between TSLP and its receptor. On the other hand, its binding and blocking of the other undisclosed target is expected to produce a synergistic effect, overcoming resistance issues associated with single-target TSLP antibodies.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/1148853674"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1148853674\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1148853674?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-10 10:18","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1148853674","market":"other","top_or_hot":-1,"title":"Clinical Trial Approval for TSLP Bispecific Antibody Boosts SKB BIO-B and HBM HOLDINGS-B Shares","media":"Stock News","content":"<p>Shares of SKB BIO-B (06990) and HBM HOLDINGS-B (02142) rose in morning trading. At the time of writing, SKB BIO-B was up 8.95%, trading at HK$414, while HBM HOLDINGS-B advanced 4.26% to HK$12. The gains followed news that on March 9, the CDE website indicated that the SKB575 (HBM7575) injection, jointly submitted by SKB BIO-B and HBM HOLDINGS-B, had received clinical trial approval for the treatment of atopic dermatitis. This marks the first bispecific antibody from the partners’ autoimmune disease collaboration pipeline to enter the clinical stage. It is reported that HBM7575/SKB575 targets thymic stromal lymphopoietin (TSLP) and an undisclosed target, featuring a dual mechanism of action. On one hand, it inhibits TSLP-mediated signaling pathways and the activation of Th2 immune cells by blocking the interaction between TSLP and its receptor. On the other hand, its binding and blocking of the other undisclosed target is expected to produce a synergistic effect, overcoming resistance issues associated with single-target TSLP antibodies.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Clinical Trial Approval for TSLP Bispecific Antibody Boosts SKB BIO-B and HBM HOLDINGS-B Shares</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nClinical Trial Approval for TSLP Bispecific Antibody Boosts SKB BIO-B and HBM HOLDINGS-B Shares\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time smaller\">2026-03-10 10:18</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Shares of SKB BIO-B (06990) and HBM HOLDINGS-B (02142) rose in morning trading. At the time of writing, SKB BIO-B was up 8.95%, trading at HK$414, while HBM HOLDINGS-B advanced 4.26% to HK$12. The gains followed news that on March 9, the CDE website indicated that the SKB575 (HBM7575) injection, jointly submitted by SKB BIO-B and HBM HOLDINGS-B, had received clinical trial approval for the treatment of atopic dermatitis. This marks the first bispecific antibody from the partners’ autoimmune disease collaboration pipeline to enter the clinical stage. It is reported that HBM7575/SKB575 targets thymic stromal lymphopoietin (TSLP) and an undisclosed target, featuring a dual mechanism of action. On one hand, it inhibits TSLP-mediated signaling pathways and the activation of Th2 immune cells by blocking the interaction between TSLP and its receptor. On the other hand, its binding and blocking of the other undisclosed target is expected to produce a synergistic effect, overcoming resistance issues associated with single-target TSLP antibodies.</p>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0196878994.USD","symbol_name":"MANULIFE GF CHINA VALUE \"AA\" (USD) INC","start_time":0,"source_url":"","article_id":"1148853674","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1148853674","pubTimestamp":1773109105,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Shares of SKB BIO-B (06990) and HBM HOLDINGS-B (02142) rose in morning trading. At the time of writing, SKB BIO-B was up 8.95%, trading at HK$414, while HBM HOLDINGS-B advanced 4.26% to HK$12. The...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0196878994.USD":"MANULIFE GF CHINA VALUE \"AA\" (USD) INC","02142":"和铂医药-B","06990":"科伦博泰生物-B","BK1583":"高瓴概念","BK1161":"生物科技","BK4588":"碎股","BK4585":"ETF&股票定投概念","BK1574":"生物医药B类股","VXUS":"国际股票ETF-Vanguard"},"translate_title":"TSLP双特异性抗体临床试验获批提振SKB BIO-B和HBM HOLDINGS-B股","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VXUS":1,"06990":1,"02142":1},"content_text":"Shares of SKB BIO-B (06990) and HBM HOLDINGS-B (02142) rose in morning trading. At the time of writing, SKB BIO-B was up 8.95%, trading at HK$414, while HBM HOLDINGS-B advanced 4.26% to HK$12. The gains followed news that on March 9, the CDE website indicated that the SKB575 (HBM7575) injection, jointly submitted by SKB BIO-B and HBM HOLDINGS-B, had received clinical trial approval for the treatment of atopic dermatitis. This marks the first bispecific antibody from the partners’ autoimmune disease collaboration pipeline to enter the clinical stage. It is reported that HBM7575/SKB575 targets thymic stromal lymphopoietin (TSLP) and an undisclosed target, featuring a dual mechanism of action. On one hand, it inhibits TSLP-mediated signaling pathways and the activation of Th2 immune cells by blocking the interaction between TSLP and its receptor. On the other hand, its binding and blocking of the other undisclosed target is expected to produce a synergistic effect, overcoming resistance issues associated with single-target TSLP antibodies.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}